HUTCHMED (China) Limited H7T1.F Stock
HUTCHMED (China) Limited Price Chart
HUTCHMED (China) Limited H7T1.F Financial and Trading Overview
HUTCHMED (China) Limited stock price | 17.6 EUR |
Previous Close | 11.4 EUR |
Open | 11.8 EUR |
Bid | 11.8 EUR x 50000 |
Ask | 12.7 EUR x 50000 |
Day's Range | 11.8 - 11.8 EUR |
52 Week Range | 7.45 - 18.5 EUR |
Volume | 500 EUR |
Avg. Volume | 10 EUR |
Market Cap | 2.11B EUR |
Beta (5Y Monthly) | 0.883908 |
PE Ratio (TTM) | N/A |
EPS (TTM) | 0.56 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 47.39 EUR |
H7T1.F Valuation Measures
Enterprise Value | 1.3B EUR |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 4.9453244 |
Price/Book (mrq) | 3.2686982 |
Enterprise Value/Revenue | 3.039 |
Enterprise Value/EBITDA | -3.247 |
Trading Information
HUTCHMED (China) Limited Stock Price History
Beta (5Y Monthly) | 0.883908 |
52-Week Change | 15.62% |
S&P500 52-Week Change | 20.43% |
52 Week High | 18.5 EUR |
52 Week Low | 7.45 EUR |
50-Day Moving Average | 12.72 EUR |
200-Day Moving Average | 12.58 EUR |
H7T1.F Share Statistics
Avg. Volume (3 month) | 10 EUR |
Avg. Daily Volume (10-Days) | 0 EUR |
Shares Outstanding | 173.23M |
Float | 89.68M |
Short Ratio | N/A |
% Held by Insiders | 0.41% |
% Held by Institutions | 16.87% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | December 31, 2022 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -84.62% |
Operating Margin (ttm) | -95.61% |
Gross Margin | -63.69% |
EBITDA Margin | -93.57% |
Management Effectiveness
Return on Assets (ttm) | -21.21% |
Return on Equity (ttm) | -42.99% |
Income Statement
Revenue (ttm) | 426.41M EUR |
Revenue Per Share (ttm) | 2.52 EUR |
Quarterly Revenue Growth (yoy) | 12.90% |
Gross Profit (ttm) | -271587000 EUR |
EBITDA | -399028992 EUR |
Net Income Avi to Common (ttm) | -360835008 EUR |
Diluted EPS (ttm) | -2.05 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 634.15M EUR |
Total Cash Per Share (mrq) | 3.75 EUR |
Total Debt (mrq) | 27.01M EUR |
Total Debt/Equity (mrq) | 4.24 EUR |
Current Ratio (mrq) | 2.373 |
Book Value Per Share (mrq) | 3.61 |
Cash Flow Statement
Operating Cash Flow (ttm) | -268599008 EUR |
Levered Free Cash Flow (ttm) | -190379632 EUR |
Profile of HUTCHMED (China) Limited
Country | Germany |
State | N/A |
City | Central |
Address | Cheung Kong Center |
ZIP | N/A |
Phone | 852 2121 8200 |
Website | https://www.hutch-med.com |
Industry | Drug Manufacturers-Specialty & Generic |
Sector(s) | Healthcare |
Full Time Employees | 1280 |
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; HMPL-A83, an investigational IgG4-type humanized anti-CD47 monoclonal antibody; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.
Q&A For HUTCHMED (China) Limited Stock
What is a current H7T1.F stock price?
HUTCHMED (China) Limited H7T1.F stock price today per share is 17.6 EUR.
How to purchase HUTCHMED (China) Limited stock?
You can buy H7T1.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for HUTCHMED (China) Limited?
The stock symbol or ticker of HUTCHMED (China) Limited is H7T1.F.
Which industry does the HUTCHMED (China) Limited company belong to?
The HUTCHMED (China) Limited industry is Drug Manufacturers-Specialty & Generic.
How many shares does HUTCHMED (China) Limited have in circulation?
The max supply of HUTCHMED (China) Limited shares is 170.73M.
What is HUTCHMED (China) Limited Price to Earnings Ratio (PE Ratio)?
HUTCHMED (China) Limited PE Ratio is 31.42857200 now.
What was HUTCHMED (China) Limited earnings per share over the trailing 12 months (TTM)?
HUTCHMED (China) Limited EPS is 0.56 EUR over the trailing 12 months.
Which sector does the HUTCHMED (China) Limited company belong to?
The HUTCHMED (China) Limited sector is Healthcare.